MedTrace Logo

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2011-03-01

No results posted yet for this study

Summary

RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment.

PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Conditions

Interventions

DRUG

carboplatin

DRUG

cisplatin

DRUG

docetaxel

DRUG

etoposide

DRUG

paclitaxel

DRUG

vinblastine sulfate

DRUG

vinorelbine tartrate

GENETIC

gene expression analysis

PROCEDURE

positron emission tomography

RADIATION

fludeoxyglucose F 18

RADIATION

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • American College of Radiology Imaging Network

    lead NETWORK

Principal Investigators

  • Mitchell Machtay, MD · Sidney Kimmel Cancer Center at Thomas Jefferson University

Study Design

Purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-06-30

Countries

  • United States
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083083 on ClinicalTrials.gov